Document:

Supply Agreement dated as of June 26, 1995

 Exhibit 10.20 
  
 S U P P L Y   A G R E E M E N T 
  
 This Supply Agreement (the “SUPPLY AGREEMENT”), entered into as of June 26, 1995 (the “EFFECTIVE DATE”), is made by and
between 
  
 ASTRA AB, a corporation organized and existing under the laws of
Sweden, S-151 85 Sodertalje, Sweden (“ASTRA”) 
  
 and 
  
 CENTAUR PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the
State of Delaware, 484 Oakmead Parkway, Sunnyvale CA 94086, USA (“CENTAUR”). 
  
 WITNESSETH 
  
 WHEREAS
CENTAUR under a Development, License and Marketing Agreement (the “LICENSE AGREEMENT”) dated as of the Effective Date has granted ASTRA certain worldwide rights to exploit Licensed Product under the CENTAUR Technology and Product Know-How
(all as more particularly set forth in the License Agreement); and 
  
 WHEREAS ASTRA wishes to purchase from CENTAUR and CENTAUR wishes to manufacture and supply ASTRA with Substance to be included in Licensed Product, initially synthesized in smaller quantities for pre-clinical and clinical use and, later, on
a full commercial scale. 
  
 NOW THEREFORE, in consideration of
the promises and mutual covenants herein contained, the parties agree as follows: 
  

	1.	DEFINITIONS 

  
 As used herein, the following terms have the following meanings: 
  

	1.1	“AFFILIATE” shall have the meaning given in the License Agreement. 

  

	1.2	“ASTRA LICENSE” shall have the meaning provided in Section 2.1 of the License Agreement. 

  

	1.3	“BANKRUPTCY” shall have the meaning provided in Paragraph 10.3 hereof. 

  

	1.4	“CENTAUR TECHNOLOGY” shall have the meaning provided in the License Agreement. 

  

	[*]	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES EXCHANGE ACT OF 1933, AS AMENDED. 

  

 -1- 

 Agreement. 
  

	1.5	“CONFIDENTIAL INFORMATION” shall have the meaning provided in the License Agreement. 

  

	1.6	“DEFAULT” shall have the meaning provided in Paragraph 10.2 hereof. 

  

	1.7	“FIELD” shall have the meaning provided in the License Agreement. 

  

	1.8	“FORCE MAJEURE PERIOD” shall have the meaning provided in Paragraph 6.3 hereof. 

  

	1.9	“FORCE MAJEURE PERIOD AS EXTENDED” shall have the meaning provided in Paragraph 6.3 hereof. 

  

	1.10	“FORCE MAJEURE SUPPLY PAYMENTS” shall have the meaning provided in Paragraph 6.3 hereof. 

  

	1.11	“LICENSE AGREEMENT” means the Development, License and Marketing Agreement entered into by CENTAUR and ASTRA on the same date as this Supply Agreement, under which
CENTAUR has granted ASTRA certain rights to commercialize Licensed Product throughout the world. 

  

	1.12	“MANUFACTURING COST” means CENTAUR’s actual cost for the manufacture of Substance, not including any development costs, and calculated as the sum of the
following, all determined in accordance with generally accepted accounting practices: 

  

	 	(a)	Direct material cost; and 

  

	 	(b)	Direct labor cost, including benefits; and 

  

	 	(c)	A fair portion of manufacturing overhead and indirect manufacturing costs; and 

  

	 	(d)	A fair portion of administrative costs; and 

  

	 	(e)	Quality control; and 

  

	 	(f)	Handling and warehousing costs. 

  
 Where standard cost is employed, such cost of production will include normal variances, e.g. price variances, yield variances and other variances
associated with the relevant production. 
  

 -2- 

	1.13	“OKLAHOMA/KENTUCKY LICENSE” shall have the meaning provided in the License Agreement. 

  

	1.14	“PRODUCT KNOW-HOW” means all enabling information with respect to production and quality control of Substance (including patented processes), now owned by or
licensed to CENTAUR or hereinafter acquired or developed by CENTAUR or ASTRA during the Term of this Supply Agreement. 

  

	1.15	“RECOMMENCEMENT NOTICE” shall have the meaning provided in Paragraph 6.3 hereof. 

  

	1.16	“SPECIFICATIONS” shall have the meaning provided in Paragraph 7.1 hereof. 

  

	1.17	“STEERING COMMITTEE” shall have the meaning provided in the License Agreement. 

  

	1.18	“SUBSTANCE(S)” means the active ingredient(s) included in Licensed Product. 

  
 Other capitalized terms not defined herein shall have the meaning provided in the License Agreement, unless the context
clearly requires otherwise. In case of a conflict between this Supply Agreement and the License Agreement, the License Agreement shall govern. 
  

	1.19	“TERM” shall have the meaning provided in Paragraph 10.1 hereof. 

  

	2.	REGULATORY CLEARANCE 

  

	2.1	CENTAUR TO SECURE REGULATORY APPROVALS. CENTAUR will use its best reasonable efforts in the performance of its obligations under this Supply Agreement to obtain all
regulatory approvals necessary or appropriate for the manufacture or supply of Substance for Licensed Product and promptly provide ASTRA with such information regarding the manufacture and quality control of Substance for Licensed Product necessary
to permit ASTRA to secure approvals to carry out clinical studies and for marketing authorization of Licensed Product worldwide. CENTAUR’s obligations to obtain regulatory approvals shall include, without limitation, the following:

  

	 	(a)	 MANUFACTURING APPROVAL. CENTAUR will prepare a Drug Master File and/or a Plant Master File, as applicable for each Substance (collectively the
“DOCUMENTATION”) in accordance with 

  

 -3- 

	 	 
the requirements of relevant regulatory authorities in countries where ASTRA intends to use and sell Licensed Product. The Documentation will comply with
relevant regulations and standards existing from time to time in the EC countries, the United States and Japan. 

  

	 	(b)	RIGHT OF REFERENCE. CENTAUR will provide to all regulatory authorities and to ASTRA (i) on filing of its Drug Master File or Plant Master File, and thereafter for new
filings, (ii) at the time of submission of an NDA, any statement or other document necessary or appropriate to permit and authorize ASTRA or ASTRA’s sublicensees to cross-reference CENTAUR’s Drug Master File or Plant Master File when and
as deemed necessary by ASTRA. 

  

	 	(c)	GOOD MANUFACTURING PRACTICES. CENTAUR will undertake such steps to insure, with respect to each Substance, manufacturing compliance with all regulatory approvals, including,
without limitation, “GOOD MANUFACTURING PRACTICES” and will permit ASTRA to conduct GMP audits at CENTAUR’s manufacturing facilities from time to time. 

  

	 	(d)	REGULATORY INSPECTION. Should any national or international regulatory authority give notice of intent to conduct an inspection at CENTAUR’s manufacturing plant or take
any other regulatory action with respect to the manufacture and supply of Substance, CENTAUR will promptly give ASTRA notice thereof, supply all information pertinent thereto, and ASTRA shall have the right, but not the obligation, to be present and
take part in any such inspection or regulatory action. 

  

	 	(e)	CONTACT WITH REGULATORY AUTHORITIES. CENTAUR will be responsible for all contacts with the regulatory authorities with respect to the Documentation after it has been
submitted to the relevant authority and will continuously keep the Documentation updated (with copies to ASTRA) with respect to developments and changes in production methods, quality, specifications or in other respects of the Licensed Product.

  

	 	(f)	REGULATORY APPROVAL – LICENSED PRODUCT. CENTAUR will use its best reasonable efforts to assist ASTRA in providing to regulatory authorities all information with respect
to the manufacture or quality control of Substance necessary for regulatory approval of Licensed Product. 

  

 -4- 

	 	(g)	REFERENCE STANDARD. CENTAUR shall provide ASTRA from time to time with reasonable quantities of Substance of reference standard quality for analytical purposes.

  

	 	(h)	CENTAUR TO INFORM ASTRA. With respect to CENTAUR’s undertakings set forth in this Paragraph 2.1 hereof, CENTAUR shall regularly inform ASTRA of the status of such
undertakings including, without limitation, the preparation and progress of Documentation. All Documentation shall be subject to ASTRA’s prior written approval prior to submission by CENTAUR to regulatory authorities. 

 
 ASTRA will collaborate with CENTAUR in the performance of CENTAUR’s undertakings
pursuant to Paragraph 2.1 hereof and shall provide documents in ASTRA’s possession which would assist CENTAUR with respect to such obligations. 
  

	3.	CENTAUR COMPENSATION 

  

	3.1	TOTAL COMPENSATION. As total compensation to CENTAUR for CENTAUR’s obligations undertaken pursuant to this Supply Agreement and the supply of Substance for Licensed
Product, ASTRA shall pay to CENTAUR a supply price as follows: 

  

	 	(a)	CLINICAL TRIALS AND SAMPLING. The supply price paid by ASTRA for all Substance (and any placebo or other materials, implant or device) used in pre-clinical and clinical
trials of Licensed Product shall be an amount equal to [*]. 

  

	 	(b)	COMMERCIAL SALES. The supply price paid by ASTRA for all Substance, other than that covered by Paragraph 3.1(a) hereof, shall be an amount equal to [*]. CENTAUR shall use its
best reasonable efforts at all times to minimize Manufacturing Cost. 

  

	4.	SUPPLY FOR PRE-CLINICAL AND CLINICAL USE 

  

	4.1	 PRE-CLINICAL AND CLINICAL SUPPLIES OF SUBSTANCE. Subject to the provisions of this Supply Agreement, and to ASTRA taking over some or all of the manufacture
and supply of Substance for Licensed Product, as contemplated by 

  

 -5- 

	 	 
Paragraphs 6.2, 6.3 and 11.2 hereof, CENTAUR will manufacture and supply all Substance for Licensed Product required by ASTRA and its sublicensees, including
substance for pre-clinical and clinical trials. 

  

	4.2	FORECAST AND DELIVERY SCHEDULE. CENTAUR undertakes to supply Substance for pre-clinical and clinical use within sixty (60) days of ASTRA’s firm order. ASTRA will give
CENTAUR forecasts of its expected need of Substance for pre-clinical and clinical use in such manner as agreed upon in the Steering Committee. 

  

	5.	SUPPLY FOR COMMERCIAL USE 

  

	5.1	SUPPLY FOR COMMERCIAL USE. CENTAUR undertakes on an exclusive basis to manufacture and supply Substance to ASTRA for commercial use in the Field. 

  

	5.2	FORECAST. ASTRA will, before each January 1, April 1, July 1 and October 1, present to CENTAUR a written forecast estimating the quantities of Substance to be delivered
during each of the next fifteen (15) months. 

  

	5.3	FIRM ORDERS. ASTRA will place firm orders for delivery not less than ninety (90) days prior to the required shipment date, and CENTAUR will be obliged to deliver all ordered
Substance by the delivery date stated in the order, except to the extent that such supply would exceed the latest forecast given by more than twenty percent (20%) for the month in question. 

  

	5.4	DELIVERY TERMS. Each delivery of Substance will be effected Ex Works CENTAUR’s plant, in accordance with Incoterms 1990, as published by the International Chamber of
Commerce. All quantities of Substance will be delivered suitably packed for transportation. 

  

	6.	PURCHASE UNDERTAKING AND MANUFACTURING LICENSE 

  

	6.1	EXCLUSIVE SUPPLY. Subject to Paragraphs 6.2, 6.3 and 11.2 of this Supply Agreement, ASTRA undertakes to purchase from CENTAUR all Substance needed by ASTRA for the
formulation of Licensed Product to be sold throughout the world. 

  

	6.2	ASTRA’S MANUFACTURE OF SUBSTANCE. The parties recognize the value of a second source of supply of Substance for Licensed Product for risk management and backup purposes.
ASTRA shall be entitled under the ASTRA License to manufacture or have manufactured up to ten percent (10%) of ASTRA’s (or ASTRA’s sublicensees) total requirement of Substance. 

  

 -6- 

 Notwithstanding such manufacture by ASTRA (or have manufactured), ASTRA shall, other than for Substance
with respect to the provisions of Paragraph 3.1(a) hereof, pay to CENTAUR with respect to such manufacture an amount equal to [*] of Manufacturing Cost as if such Substance had been manufactured by CENTAUR. 
  

	6.3	FORCE MAJEURE – MANUFACTURE. If for a period of three hundred sixty five (365) days or less (the “FORCE MAJEURE PERIOD”) CENTAUR shall, for reasons of force
majeure, be unable to supply ASTRA (or ASTRA’s sublicensees) with substantially all requirements of Substance for pre-clinical, clinical or commercial use, ASTRA will be free during the Force Majeure Period to manufacture or have manufactured
Substance on a commercial scale for all of ASTRA’s (or ASTRA’s sublicensees) requirements of Substance. Within ninety (90) days following commencement of a Force Majeure Period, CENTAUR shall certify by notice in writing to ASTRA (i)
CENTAUR’s intent to recommence manufacture of Substance as soon as reasonably practical, but prior to termination of the Force Majeure Period (the “RECOMMENCEMENT NOTICE”), or (ii) terminate this Supply Agreement pursuant to Paragraph
10.4 hereof, but effective as of the commencement of the Force Majeure Period. If CENTAUR delivers the Recommencement Notice, CENTAUR shall continuously advise ASTRA, from time to time, as to the date CENTAUR will recommence manufacture of
Substance, and ASTRA shall pay to CENTAUR with respect to such manufacture of Substance by ASTRA during the Force Majeure Period, an amount equal to [*] of the Manufacturing Cost, less all sums paid or payable to CENTAUR from insurance
policies for “business loss”, or “business interruption insurance” arising out of the event of force majeure (the “FORCE MAJEURE SUPPLY PAYMENTS”). Notwithstanding the Recommencement Notice, CENTAUR may, within thirty
(30) days prior to termination of the Force Majeure Period, by written notice to ASTRA, extend the Force Majeure Period, for an additional period of one hundred twenty (120) days (the “FORCE MAJEURE PERIOD AS EXTENDED”), provided that
during the Force Majeure Period As Extended, ASTRA shall make no Force Majeure Supply Payments to CENTAUR. In the event CENTAUR shall fail to recommence manufacture of Substance prior to termination of the Force Majeure Period or the Force Majeure
Period As Extended, as the case may be, CENTAUR shall be deemed to have terminated this Supply Agreement pursuant to Paragraph 10.4 hereof, effective as of the commencement of the Force Majeure Period, and ASTRA shall be entitled to a return of all
Force Majeure Supply Payments, or at ASTRA’s election, to deduct such Force Majeure Supply Payments from Net Sales royalties payable to CENTAUR pursuant to the License Agreement. 

  

 -7- 

	6.4	ASTRA IMPROVEMENTS TO PRODUCT KNOW-HOW. In the event that ASTRA develops improvements to Product Know-How, such improvements will be shared cost free with CENTAUR, which
shall be free to use said improvements in its own manufacture of Substance. 

  

	6.5	ACCESS TO CENTAUR TECHNOLOGY AND PRODUCT KNOW-HOW. In order to permit ASTRA the full use and enjoyment of the ASTRA License, CENTAUR shall, on the Effective Date and from
time to time thereafter during the Term of this Supply Agreement, make available to ASTRA all CENTAUR Technology and Product Know-How. 

  

	6.6	NOTIFICATION OF EVENTS CONCERNING SUPPLY. CENTAUR will promptly notify ASTRA of any circumstances that may be of importance as to CENTAUR’s ability to supply ASTRA with
Substance. In the event ASTRA should commence manufacture of Substance as provided herein, CENTAUR will support ASTRA or its nominee in setting up a well functioning production, i.a. by furnishing ASTRA or its nominee with information, know-how and
advice regarding processing and choice of machinery, equipment, etc. 

  

	7.	QUALITY 

  

	7.1	GUARANTY OF QUALITY. CENTAUR covenants and warrants that the quality of Substance to be supplied by CENTAUR hereunder shall correspond to the most stringent of the following:
(i) CENTAUR standards, (ii) the mutually established specifications to be subsequently annexed to this Supply Agreement as Appendix A, (iii) the applicable provisions of the U.S. Food, Drug and Cosmetic Act and corresponding regulations
within EC and Japan, and (iv) all applicable GMP standards (alternatively the “SPECIFICATIONS”). 

  

	7.2	ASTRA INSPECTION. Within sixty (60) days following receipt of each shipment and before Substance is put into further production, whichever is first to occur, ASTRA shall
carry out customary tests and inspections as separately agreed between the parties. Should any quantity of Substance be found not to conform with the Specifications, CENTAUR shall, at its sole cost, replace the defective quantity without delay,
provided that ASTRA has notified CENTAUR of such non-conformity within ninety (90) days following receipt of the defective quantity of Substance. 

  

	7.3	CHANGES IN MANUFACTURING PROCESS. No changes shall be made in the processes or specifications used in producing Substance for Licensed Product without agreement by both
parties. If such changes are required for regulatory reasons, neither party shall unreasonably withhold its consent to such changes. 

  

 -8- 

	7.4	INSPECTION. ASTRA shall be entitled to visit and inspect any CENTAUR’s manufacturing site involved in the manufacture of Substance at any reasonable time, upon prior
notice. 

  

	7.5	COMPLIANCE. CENTAUR covenants and warrants that all production of Substance carried out hereunder will be performed in compliance with (i) the Specifications, (ii) applicable
law, (iii) applicable Good Manufacturing Practice (GMP), and (iv) relevant health and environmental authorities’ directions. 

  

	8.	REPRESENTATIONS AND WARRANTIES 

  

	8.1	GENERAL REPRESENTATIONS. Each party hereby represents and warrants to the other as follows: 

  

	 	(a)	DULY ORGANIZED. It is a corporation duly organized, validly existing and is in good standing under the laws of the jurisdiction of its incorporation, is qualified to do
business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and has all requisite power and authority, corporate or otherwise, to
conduct its business as now being conducted, to own, lease and operate its properties and to execute, deliver and perform this Supply Agreement. 

  

	 	(b)	DUE EXECUTION. The execution, delivery and performance by it of this Supply Agreement have been duly authorized by all necessary corporate action and do not and will not (i)
require any consent or approval of its stockholders, (ii) violate any provision of any law, rule, regulation, order, writ, judgment, injunction, decree, determination or award presently in effect having applicability to it or any provision of its
charter or by-laws, or (iii) result in a breach of or constitute a default under any material agreement, mortgage, lease, license, permit, patent or other instrument or obligation to which it is a party or by which it or its assets may be bound or
affected. 

  

	 	(c)	NO THIRD PARTY APPROVAL. No authorization, consent, approval, license, exemption of, or filing or registration with, any court or governmental authority or regulatory body is
required for the due execution, delivery or performance by it of this Supply Agreement. 

  

 -9- 

	 	(d)	BINDING AGREEMENT. This Supply Agreement is a legal, valid and binding obligation of such party, enforceable against it in accordance with its terms and conditions, except as
may be limited by bankruptcy laws or other laws affecting the rights of creditors generally, and rules of law governing equitable remedies. It is not under any obligation to any person, contractual or otherwise, that is conflicting or inconsistent
in any respect with the terms of this Supply Agreement or that would impede the diligent and complete fulfillment of its obligations hereunder. 

  

	 	(e)	GOVERNMENTAL STATUS. It is not debarred or suspended from receiving contracts from the United States or Swedish government or other governmental authority or agency.

  

	 	(f)	FULL DISCLOSURE. Each party has disclosed to the other in good faith any and all material information relevant to the subject matter of this Supply Agreement and to such
party’s ability to observe and perform its obligations hereunder, and each party covenants on and after the Effective Date to provide to the other such additional material information which may, or with the passage of time, effect the subject
matter of this Supply Agreement or the ability of such party to observe and perform its obligations hereunder. 

  

	8.2	CENTAUR REPRESENTATIONS. CENTAUR covenants, represents and warrants to ASTRA that 

  

	 	(a)	CENTAUR is the owner or licensee, as the case may be, of the CENTAUR Technology and Product Know-How and the same are free of any liens, encumbrances, restrictions and other legal
or equitable claims of any kind or nature, excepting the rights of grantors of the CENTAUR Licenses, 

  

	 	(b)	CENTAUR has the right to grant the ASTRA License, and 

  

	 	(c)	CENTAUR has not granted and will not grant during the Term of this Supply Agreement any license or sublicense of the CENTAUR Licenses, CENTAUR Technology and Product Know-How in the
Field. 

  

 -10- 

	9.	CONFIDENTIAL INFORMATION 

  

	9.1	CONFIDENTIAL INFORMATION. Confidential Information shall be treated as provided in the License Agreement. 

  

	10.	TERM AND TERMINATION 

  

	10.1	TERM. The Term of this Supply Agreement (the “TERM”) shall commence as of the Effective Date. Unless sooner terminated pursuant to Paragraphs 10.2 or 10.3 hereof,
the Term of this Supply Agreement shall expire at such time as the License Agreement expires. 

  

	10.2	DEFAULT. Failure by either party to comply with any of its material obligations contained in this Supply Agreement following notice and opportunity to cure, as hereinafter
provided (a “DEFAULT”) shall entitle the other party to terminate this Supply Agreement. The non- defaulting party shall give the other party notice specifying the nature of the breach of this Supply Agreement and requiring it to cure. If
such breach is not cured within ninety (90) days after the receipt of such notice (or one hundred twenty (120) days in event such breach cannot be reasonably expected to be cured within ninety (90) days, and the defaulting party gives notice to the
other party of its inability to cure such breach within a 90-day period and the defaulting party thereafter uses reasonable efforts to cure such breach as soon as practicable, but in no event longer than one hundred twenty (120) days), the notifying
party shall be entitled, without prejudice to any of its other rights under this Supply Agreement, and in addition to any other remedies available to it by law or in equity, to terminate this Supply Agreement by giving notice to that effect to the
defaulting party. The right of either party to terminate this Supply Agreement, as hereinabove provided, shall not be affected in any way by its waiver or failure to take action with respect to any previous Default. Notwithstanding the foregoing,
and other than as provided in Paragraph 10.3 hereof, a party shall not have a right to terminate this Supply Agreement in the event the other party pursuant to Paragraph 12 has sought to resolve the dispute for which termination is being sought.

  

	10.3	 INSOLVENCY OR BANKRUPTCY. Either party may, in addition to any other remedies available to it by law or in equity, terminate this Supply Agreement by written
notice to the other party in the event (i) the other party shall have become insolvent or bankrupt, or shall have made an assignment for the benefit of its creditors, or (ii) there shall have been appointed a trustee or receiver of the other party
or for all or a substantial part of its property, or (iii) any case or proceeding shall have been commenced or some other action taken by or against the other party in bankruptcy or seeking reorganization, liquidation, 

  

 -11- 

	 	 
dissolution, winding-up, arrangement, composition or readjustment of its debts or any other relief under any bankruptcy, insolvency, reorganization or other
similar act or law of any jurisdiction now or hereafter in effect or there shall have been issued a warrant of attachment, execution, distraint or similar process against any substantial part of the property of the other party, and any such event or
action (except where a party voluntarily takes such actions (e.g., where a party makes a bankruptcy filing)) shall have continued for ninety (90) days undismissed, unbounded and undischarged (alternatively a “BANKRUPTCY”); provided,
however, that no such right to terminate shall pertain solely by virtue of a voluntary reorganization for the purpose of solvent amalgamation or reconstruction. 

  

	10.4	TERMINATION BY CENTAUR. CENTAUR may, on six (6) months’ prior notice to ASTRA terminate this Supply Agreement, whereupon CENTAUR shall provide all reasonable assistance
to ASTRA pursuant to Paragraph 6.5 hereof to establish a manufacturing facility for Substance. 

  

	10.5	EFFECT OF TERMINATION OF SUPPLY AGREEMENT. 

  

	 	(a)	EXISTING OBLIGATIONS. Upon termination of this Supply Agreement for any reason, nothing herein shall be construed to release either party from any obligation that matured
prior to the effective date of such termination. 

  

	 	(b)	MANUFACTURE OF SUBSTANCE BY ASTRA. Upon termination of this Supply Agreement pursuant to Paragraphs 6.3, 10.1, 10.4, a Default or Bankruptcy by CENTAUR pursuant to Paragraphs
10.2 or 10.3 or a Takeover Event pursuant to Paragraph 11.2 hereof, ASTRA shall be entitled pursuant to the ASTRA License to the exclusive worldwide right and license to manufacture, or have manufactured, Substance for Licensed Product for ASTRA
(and ASTRA’s sublicensees), without compensation to CENTAUR pursuant to this Supply Agreement. 

  

	 	(c)	EXPIRATION OF TERM OR CENTAUR DEFAULT OR BREACH. Upon termination of this Supply Agreement (i) at the expiration of the Term, or (ii) by ASTRA as a result of (x) a Default by
CENTAUR hereunder or under the License Agreement, or (y) the Bankruptcy of CENTAUR, or (iii) by CENTAUR pursuant to Paragraph 10.4 hereof, the following provisions of this Supply Agreement shall survive such termination: 

  

	 Paragraph 11.12
	 	–	  	CENTAUR Indemnification

  

 -12- 

	 Paragraph 11.14
	 	–	  	Governing Law
	 Paragraph 12
	 	–	  	Resolution of Disputes

  

	 	(d)	EXPIRATION OF TERM OR ASTRA DEFAULT OR BREACH. Upon the termination of this Supply Agreement (i) at the expiration of the Term, or (ii) by CENTAUR as a result of (x) a
Default by ASTRA hereunder or under the License Agreement, or (y) the Bankruptcy of ASTRA, the following provisions of this Supply Agreement shall survive such termination: 

  

	 Paragraph 6.4
	 	–	  	ASTRA’s Improvements to Product Know-How
	 Paragraph 11.11
	 	–	  	ASTRA Indemnification
	 Paragraph 10.14
	 	–	  	Governing Law
	 Paragraph 12
	 	–	  	Resolution of Disputes

  

	11.	MISCELLANEOUS PROVISIONS 

  

	11.1	NO PARTNERSHIP. Nothing in this Supply Agreement is intended or shall be deemed to constitute a partnership, agency, employer, employee or joint venture relationship between
the parties. Neither party shall incur any debts or make any commitments for the other. 

  

	11.2	ASSIGNMENTS. Except as otherwise provided herein, neither this Supply Agreement nor any interest hereunder shall be assignable by either party by operation of law or
otherwise without the prior written consent of the other; provided, however, that either party may assign this Supply Agreement to any wholly-owned subsidiary or to any successor by merger or sale of substantially all of its assets to which this
Supply Agreement relates in a manner such that the assignor shall remain liable and responsible for the performance and observance of all its duties and obligations hereunder, or if the assignor disappears because of such transaction, the assignee
must agree to abide by the terms and conditions of this Supply Agreement, provided, however, that if a third party engaged in the manufacture and/or sale of pharmaceutical products acquires in one (1) or a series of transactions more than thirty
percent (30%) of the capital stock of CENTAUR entitled to vote for directors (the “TAKEOVER EVENT”), ASTRA may, at its option, within one hundred eighty (180) days following notice to ASTRA of such Takeover Event, upon twelve (12)
months’ prior notice to CENTAUR, terminate this Supply Agreement, in which event ASTRA may undertake the manufacture of Substance for Licensed Product for ASTRA’s (and ASTRA’s sublicensees) use worldwide pursuant to Paragraph 10.5(b).

  

 -13- 

	11.3	FORCE MAJEURE. Neither party shall be liable to the other for loss or damages or shall have any right to terminate this Supply Agreement for any default or delay (including,
without limitation, an inability to supply Licensed Product) attributable to any act of God, earthquake, flood, fire, explosion, strike, lockout, labor dispute, casualty or accident, war, revolution, civil commotion, act of public enemies, blockage
or embargo, injunction, law, order, proclamation, regulation, ordinance, demand or requirement of any government or subdivision, authority (including, without limitation, drug regulatory authorities) or representative of any such government, or any
other cause beyond the reasonable control of such party, if the party affected shall give prompt notice of any such cause to the other party. The party providing such notice shall thereupon be excused from such of its obligations hereunder as it is
so disabled and for thirty (30) days thereafter, subject, however, to CENTAUR’s obligations pursuant to Paragraph 6.3 hereof as regards the Force Majeure Period. 

  

	11.4	NO TRADEMARK RIGHTS. No right, express or implied, is granted by this Supply Agreement to use in any manner any trade name or trademark of CENTAUR or ASTRA in connection with
the performance of this Supply Agreement or the exploitation of any license granted hereunder; each party may make any legally required reference to the other in connection with such manufacture or sale of Licensed Product. 

 

	11.5	PUBLIC ANNOUNCEMENTS. Copies of press releases or similar written communications containing a party’s name shall be provided to that party prior to release.

  

	11.6	ENTIRE AGREEMENT OF THE PARTIES; AMENDMENT. This Supply Agreement and the License Agreement constitutes and contains the entire understanding and agreement of the parties,
and cancels and supersedes any and all prior negotiations, correspondence and understandings and agreements, whether verbal or written, between the parties respecting the subject matter hereof. No waiver, modification or amendment of any provision
of this Supply Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each of the parties. 

  

	11.7	 SEVERABILITY. In the event any one or more of the provisions of this Supply Agreement should for any reason be held by any court or authority having
jurisdiction over this Supply Agreement or either of the parties to be invalid, illegal or unenforceable, such provision or provisions shall be validly reformed by addition or deletion of wording as appropriate to avoid such result and as nearly as
possible approximate the intent of the parties and, if unreformable, 

  

 -14- 

	 	 
shall be divisible and deleted in such jurisdiction to the extent necessary to comply with such holding, and in all other jurisdictions, this Supply
Agreement shall not be affected; provided, however, that no such reformation shall be made if the effect of such reformation would be such as to fundamentally alter the terms of this Supply Agreement beyond the intent of the parties.

  

	11.8	CAPTIONS. The captions to this Supply Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this
Supply Agreement. 

  

	11.9	NOTICE AND DELIVERY. Any notice, requests, delivery, approval or consent required or permitted to be given under this Supply Agreement shall be in writing and shall be deemed
to have been sufficiently given if delivered in person, delivered by internationally recognized courier, telegraph or sent by registered air mail letter to the party (which notice shall be considered effective when received) to whom it is directed
at its address shown below or such other address as such party shall have last given by notice to the other party. 

  
 If to CENTAUR, addressed to: 
  
 President and Chief Executive Officer 
 Centaur Pharmaceuticals, Inc. 
 484 Oakmead Parkway 
 Sunnyvale CA 94086, USA 
  
 If to
ASTRA, addressed to: 
  
 President and Chief Executive Officer

 Astra Production Chemicals AB 
 S-151 85 Sodertalje 
 Sweden 
  

	11.10	LIMITATION OF LIABILITY. Neither party shall be liable to the other for indirect, incidental or consequential damages arising out of any of the terms or conditions of this
Supply Agreement or with respect to its performance or lack thereof, except in the case of a Default resulting from a wreckless or intentional breach of its material obligations hereunder. 

  

	11.11	 ASTRA INDEMNIFICATION. ASTRA shall indemnify, defend and hold CENTAUR and each of its officers, directors, employees, agents and consultants and their
respective heirs and assigns (each a “CENTAUR INDEMNITEE”) harmless from and against all third party costs, claims, suits, expenses (including reasonable attorneys’ fees) and damages arising out of or 

  

 -15- 

	 	 
resulting from (i) the development, testing, manufacture, sale, use or promotion by ASTRA, or ASTRA’s sublicensees, of any Licensed Product, (ii) a
claim of product liability with respect to a Licensed Product (including, without limitation, a cause of action in the form of tort, warranty or strict liability), (iii) arising out of any other activity carried out by ASTRA or ASTRA’s
sublicensees pursuant to this Supply Agreement, provided, however, that the CENTAUR Indemnitee gives reasonable notice to ASTRA of any such claim or action, tenders the defense of such claim or action to ASTRA and assists ASTRA, at ASTRA’s
expense, in defending such claim or action and does not compromise or settle such claim or action without ASTRA’s prior written consent, provided, however, that ASTRA’s indemnification of CENTAUR hereunder shall not extend to any
cost, claim, suit, expense or damage which arises or results from any gross negligence or intentional misconduct of CENTAUR, or any third party for whom CENTAUR is responsible, in the manufacture of Substance for Licensed Product by CENTAUR which
results in the failure of CENTAUR to manufacture Substance for Licensed Product in accordance with the Specifications. 

  

	11.12	CENTAUR INDEMNIFICATION. CENTAUR shall indemnify, defend and hold ASTRA and each of its officers, directors, employees, agents and consultants (and their respective heirs and
assigns) (each an “ASTRA INDEMNITEE”) harmless from (i) any gross negligence or intentional misconduct of CENTAUR, or any third party for whom CENTAUR is responsible, in the manufacture of Substance for Licensed Product by CENTAUR which
results in the failure of CENTAUR to manufacture Substance for Licensed Product in accordance with the Specifications, and provided, further, that the ASTRA Indemnitee gives reasonable notice to CENTAUR of any such claims or action, tenders the
defense of such claim or action to CENTAUR and assists CENTAUR at CENTAUR’s expense in defending such claim or action and does not compromise or settle such claim or action without CENTAUR’s prior written consent. 

 

	11.13	REMEDIES CUMULATIVE. The remedies provided hereunder are cumulative and not exclusive. 

  

	11.14	GOVERNING LAW. This Supply Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to the conflict of laws provisions
thereof. 

  

	12.	RESOLUTION OF DISPUTES 

  
 12.1 DISPUTE RESOLUTION PROCESS. The parties shall resolve all disputes with respect to any matter relating to this Supply Agreement pursuant to
Section 22 of the License Agreement. 
  
  

 -16- 

 IN WITNESS WHEREOF, the parties have caused this Supply Agreement to be executed by their respective duly
authorized officers as of June 26, 1995, each copy of which shall for all purposes be deemed to be an original. 
  

	 CENTAUR PHARMACEUTICALS, INC.
	 	 	 	 ASTRA AB

	 	 	 	 	 
	 	 	 	 	 (PUBL)

					
	By:	 	 /s/    BRIAN D.
FRENZEL        

	 	 	 	By:	 	 /s/    HAKAN
MOGREN        

	 	 	 Brian D. Frenzel,
 President and
 Chief Executive Officer
 hereunto duly authorized
	 	 	 	 	 	 Hakan Mogren
 President and
 Chief Executive Officer
 hereunto duly authorized

  

 -17-Amendment to Supply Agreement , dated June 18, 2002

 Exhibit 10.21 
  
 AMENDMENT TO SUPPLY AGREEMENT 
  
 This Amendment (the “Amendment”) to the Supply Agreement dated June 26, 1995, by and between Centaur
Pharmaceuticals, Inc. and Astra AB (the “Supply Agreement”) is made this 18th day of June, 2002, by and between Centaur Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 1220 Memorex Drive, Santa Clara
CA 95050-2812 (“Centaur”) and AstraZeneca AB, successor to Astra AB, a corporation organized and existing under the laws of Sweden, S-151 85 Sodertalje, Sweden (“AstraZeneca”). Unless otherwise provided, all capitalized terms
herein shall have the meaning as set forth in the Supply Agreement or License Agreement (each as defined below), including any exhibits or amendments thereto. 
  

WHEREAS, Centaur and AstraZeneca entered into a Supply Agreement dated June 26, 1995 (the “Supply Agreement”); 
  
 WHEREAS, Centaur and AstraZeneca also entered into a Development,
License and Marketing Agreement on June 26, 1995 (as subsequently amended, the “License Agreement”); 
  
 WHEREAS, the parties are executing an amendment to the License Agreement simultaneously with this Amendment; and 
  
 WHEREAS, the parties wish to clarify and amend certain aspects of the
Supply Agreement and the License Agreement, particularly with regard to Centaur’s right to Co-Promote Licensed Product, Centaur’s right to manufacture Licensed Product, and Centaur’s right to receive royalties from AstraZeneca, given
the changes contemplated by both this Amendment and the amendment to the License Agreement. 
  
 NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, the parties hereto agree as follows: 
  

	A.	Amendment of Terms of Supply Agreement . The Supply Agreement is hereby amended as follows: 

  

	 	1.	Definitions. Sections 1.9, 1.10 and 1.15 of the Supply Agreement are hereby stricken in their entirety. 

  

	 	2.	Centaur Compensation. Section 3 of the Supply Agreement is hereby stricken in its entirety and replaced with the following: 

  

	 	“3.	Centaur Compensation: As total compensation to Centaur for Centaur’s obligations undertaken pursuant to this Supply Agreement and the supply of Substance for Licensed
Product, AstraZeneca shall pay to Centaur a supply price as follows: 

  

	 	3.1	NXY-059. The supply price paid by AstraZeneca for the Substance for NXY-059 shall be based upon the quantity ordered 

	[*]	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES EXCHANGE ACT OF 1933, AS AMENDED. 

	 	 
as further set forth in the table in Exhibit “A” hereto. The supply price to be paid by AstraZeneca pursuant to this Section 3.1 shall be adjusted
on June 30th of each year, excluding the year 2002, in accordance with the U.S. Consumer Price Index. In addition to
the supply price, AstraZeneca shall reimburse Centaur for its reasonable costs of raw materials associated with the manufacture of the Substance of NXY-059. Such costs shall be reimbursed within thirty (30) days of AstraZeneca’s receipt of
invoice for the raw material costs.” 

  

	 	3.	Supply for Pre-Clinical and Clinical Use. Section 4 of the Supply Agreement is hereby stricken in its entirety and replaced with the following: 

  

	 	“4.	Supply for Pre-Clinical and Clinical Use. 

  

	 	4.1	NXY-059. Except as otherwise provided in this Amendment or in the Supply Agreement, AstraZeneca shall manufacture one hundred percent (100%) of the Substance for NXY-059 for
its use in pre-clinical and clinical studies only.” 

  

	 	4.	Supply for Commercial Use. Section 5 of the Supply Agreement is hereby stricken in its entirety and replaced with the following: 

  

	 	“5.	Supply for Commercial Use. 

  

	 	5.1	Quantity. Except as otherwise provided in Section 5.2 below, Centaur shall have the right, but not the obligation, to manufacture and supply to AstraZeneca up to fifty
percent (50%) of all Substance for NXY-059 for AstraZeneca’s commercial needs per year, up to an annual maximum of 2,000 kg. Centaur may, at its option, assign such manufacturing and supply rights to a third party manufacturer (the
“Centaur Assignee”); provided, however, that (i) such Centaur Assignee has the requisite legal and regulatory approvals and authority to undertake such manufacturing and supply obligations, (ii) such manufacturing takes place on the
manufacturing site being used by Centaur for manufacturing at the time such assignment is made, and (iii) such assignment shall be immediately revoked if AstraZeneca, in its sole discretion, determines at any time that the Centaur Assignee does not
have the capability to manufacture and supply to AstraZeneca the quantity and quality of Substance for NXY-059 based on AstraZeneca’s assessment of the Centaur Assignee’s noncompliance with legal and regulatory obligations to undertake
such manufacturing and supply obligations or such Centaur Assignee’s inability to meet AstraZeneca’s commercial needs. 

  

	 	5.2	 Plant Validation Lots. Notwithstanding Section 5.1, to the extent permitted by applicable law or regulation, AstraZeneca shall be able to first satisfy its
commercial needs for Substance for NXY- 

  

 2 

	 	 
059 produced from its plant validation lots. Once those lots are exhausted, Centaur shall have the right, but not the obligation, to supply up to fifty
percent (50%) of all Substance for NXY-059 for AstraZeneca’s commercial needs in accordance with Section 5.1 of this Amendment, subject to Section 5.3. 

  

	 	5.3	Substance Order Methodology. On June 30th
of each year the Supply Agreement is in effect, AstraZeneca shall provide Centaur with a firm purchase order of its commercial needs for the following calendar year, up to a maximum of 2,000 kg (the “AstraZeneca Order”). Centaur shall have
the option to accept all or part of the annual AstraZeneca Order, and on or before July 31st of each year, Centaur
will firmly commit to AstraZeneca the amount of the AstraZeneca Order that it will fulfill and AstraZeneca will firmly commit to Centaur to purchase from Centaur such amount of the AstraZeneca Order. On or before September 31, Centaur and
AstraZeneca shall agree upon a delivery schedule for all Substance for NXY-059 by Centaur for the following calendar year. 

  

	 	5.4	Quality Assurance. The delivery of all Substance for NXY-059 shall be subject to the provision of a Quality Assurance Agreement to be entered into between the parties at an
appropriate time before the commencement of Centaur’s supply of substance for commercial use. 

  

	 	5.5	Payment. Payment for the Substance for NXY-059 supplied for AstraZeneca’s commercial use shall be made by AstraZeneca to Centaur within thirty (30) days of
Centaur’s delivery of the Substance for NXY-059.” 

  

	 	5.	Purchase Undertaking and Manufacturing License. Sections 6.1 (Exclusive Supply), 6.2 (Astra’s Manufacture of Substance) and 6.3 (Force Majeure – Manufacture) of the
Supply Agreement are hereby stricken in their entirety. Sections 6.4 (Astra Improvements to Product Know-How), 6.5 (Access to Centaur Technology and Product Know-How) and 6.6 (Notification of Events Concerning Supply) of the Supply Agreement remain
in full force and effect. 

  

	B.	Ratification. In all other respects, the Supply Agreement remains in full force and effect and the parties do hereby ratify the remaining terms and provisions thereof; except
to the extent any remaining terms are inconsistent with the terms of this Amendment, in which event they shall be construed in a manner consistent with the parties’ intent as set forth in this Amendment. 

  

 3 

 IN WITNESS WHEREOF, the parties have caused this Amendment to Supply Agreement to be executed by
their duly authorized representatives as of the day and year first written above. 
  

	 CENTAUR PHARMACEUTICALS, INC.
	 	 	 	 ASTRAZENECA, A.B.

					
	By:	 	  
 /s/    JOHN WALKER        

	 	 	 	By:	 	  
 /s/    GLENN ENGELMANN        

	 	 	John Walker
Chairman, and Interim
Chief Executive Officer	 	 	 	 	 	Glenn Engelmann
Authorized Signatory

  

 4 

 Exhibit A 
  

Centaur Purchase Cost Table 
 Per KG 
 (Excluding Raw Materials) 
 Based on Annual Ordered Quantity

 Subject to Annual CPI adjustments 
 [*] 

 

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}]]